The mitochondrial protease ClpP is a druggable target that controls VSMC phenotype by a SIRT1-dependent mechanism

Felipe Paredes, Holly C. Williams, Xuesong Liu, Claire Holden, Bethany Bogan, Yu Wang, Kathryn M. Crotty, Samantha M. Yeligar, Alvaro A. Elorza, Zhiyong Lin, Amir Rezvan, Alejandra San Martin

Research output: Contribution to journalArticlepeer-review

Abstract

Vascular smooth muscle cells (VSMCs), known for their remarkable lifelong phenotypic plasticity, play a pivotal role in vascular pathologies through their ability to transition between different phenotypes. Our group discovered that the deficiency of the mitochondrial protein Poldip2 induces VSMC differentiation both in vivo and in vitro. Further comprehensive biochemical investigations revealed Poldip2's specific interaction with the mitochondrial ATPase caseinolytic protease chaperone subunit X (CLPX), which is the regulatory subunit for the caseinolytic protease proteolytic subunit (ClpP) that forms part of the ClpXP complex – a proteasome-like protease evolutionarily conserved from bacteria to humans. This interaction limits the protease's activity, and reduced Poldip2 levels lead to ClpXP complex activation. This finding prompted the hypothesis that ClpXP complex activity within the mitochondria may regulate the VSMC phenotype. Employing gain-of-function and loss-of-function strategies, we demonstrated that ClpXP activity significantly influences the VSMC phenotype. Notably, both genetic and pharmacological activation of ClpXP inhibits VSMC plasticity and fosters a quiescent, differentiated, and anti-inflammatory VSMC phenotype. The pharmacological activation of ClpP using TIC10, currently in phase III clinical trials for cancer, successfully replicates this phenotype both in vitro and in vivo and markedly reduces aneurysm development in a mouse model of elastase-induced aortic aneurysms. Our mechanistic exploration indicates that ClpP activation regulates the VSMC phenotype by modifying the cellular NAD+/NADH ratio and activating Sirtuin 1. Our findings reveal the crucial role of mitochondrial proteostasis in the regulation of the VSMC phenotype and propose the ClpP protease as a novel, actionable target for manipulating the VSMC phenotype.

Original languageEnglish
Article number103203
JournalRedox Biology
Volume73
DOIs
Publication statusPublished - Jul 2024

Keywords

  • Aneurysms
  • Clpp
  • ClpXP complex
  • Metabolism
  • Mitochondria
  • NAD
  • Sirtuin 1
  • TIC10
  • Vascular smooth mucle cell
  • Vasculature
  • VSMC

ASJC Scopus subject areas

  • Organic Chemistry

Fingerprint

Dive into the research topics of 'The mitochondrial protease ClpP is a druggable target that controls VSMC phenotype by a SIRT1-dependent mechanism'. Together they form a unique fingerprint.

Cite this